Celldex Halts Barzolvolimab Development for Atopic Dermatitis After Phase 2 Miss
Celldex’s Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications.